G Medical Innovations Holdings (G Medical Innovations Holdings) ROCE % : 0.00% (As of Dec. 2022)

View and export this data going back to 2017. Start your Free Trial

What is G Medical Innovations Holdings ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. G Medical Innovations Holdings's annualized ROCE % for the quarter that ended in Dec. 2022 was 0.00%.

G Medical Innovations Holdings ROCE % Historical Data

The historical data trend for G Medical Innovations Holdings's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

G Medical Innovations Holdings ROCE % Chart

G Medical Innovations Holdings Annual Data

Trend

Sep16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

ROCE %

Get a 7-Day Free Trial

-173.17

G Medical Innovations Holdings Semi-Annual Data
	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22
ROCE %	Get a 7-Day Free Trial							-	-332.33	-270.00	-1,865.33	-

G Medical Innovations Holdings ROCE % Calculation

G Medical Innovations Holdings's annualized ROCE % for the fiscal year that ended in Dec. 2022 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	-9.864	/	( ( (10.517 - 8.281)	+	(4.825 - 9.113) )	/ 2 )
	=	-9.864	/	( (2.236	+	-4.288)	/ 2 )
	=	-9.864	/	-1.026
	=	961.40 %

G Medical Innovations Holdings's ROCE % of for the quarter that ended in Dec. 2022 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2022 )		(Q: Jun. 2022 )		(Q: Dec. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2022 )		(Q: Jun. 2022 )		(Q: Dec. 2022 )
	=	-1.998	/	( ( (10.278 - 10.613)	+	(4.825 - 9.113) )	/ 2 )
	=	-1.998	/	( ( -0.335	+	-4.288 )	/ 2 )
	=	-1.998	/	-2.3115
	=	0 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2022) EBIT data.

G Medical Innovations Holdings (OTCPK:GMVDF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

G Medical Innovations Holdings ROCE % Related Terms

Thank you for viewing the detailed overview of G Medical Innovations Holdings's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

G Medical Innovations Holdings (G Medical Innovations Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » G Medical Innovations Holdings Ltd (OTCPK:GMVDF) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

5 Oppenheimer Street, Rehovot, ISR, 7670105

Website

https://www.gmedinnovations.com

G Medical Innovations Holdings Ltd is a mobile health (mHealth), telemedicine solutions, and monitoring service platforms. It develops and markets clinical and consumer medical-grade health monitoring solutions and offers end-to-end support for e-health projects. The company offers a suite of both consumer and clinical grade products and platforms which are positioned to reduce inefficiencies in healthcare delivery, improve access, reduce costs, increase the quality of care, and make healthcare more personalized and precise. Its operating segment includes Products, Patient Services, and Covid-19 testing. The company generates maximum revenue from the Patient Services segment.

Executives

Awm Investment Company, Inc.

10 percent owner

527 MADISON AVENUE, SUITE 2600, NEW YORK NY 10022